Full Press Release Details
GAITHERSBURG, Md., May 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the BofA Securities 2024 Health Care Conference.
| Conference Details: | ||
| Fireside Chat | ||
| Date: | Wednesday, May 15, 2024 | |
| Time: | 3:00 – 3:30 p.m. Pacific Daylight Time (PDT) | |
| Location: | Encore Hotel in Las Vegas, NV | |
| Moderator: | Alec Stranahan, PhD, Equity Research – U.S. Biopharma | |
| Novavax participant: | John C. Jacobs, President and Chief Executive Officer | |
| Conference | ||
| Event: | Investor Meetings | |
| Date: | Wednesday, May 15, 2024 |
A replay of the recorded fireside session will be available through the Events & Presentations page of the Company's website at ir.novavax.com for 30 days from the date of the conference.
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information.
SOURCE Novavax, Inc.
21 %
more press release views with